Aortic stenosis (AS) is the most common valve disease. Aortic valve replacement (AVR) is the treatment of choice in symptomatic patients with severe AS. Our objective was to assess the prognostic value of NT-proBNP in Algerian patients with asymptomatic moderate/ severe aortic. Prospective study of 225 patients with degenerative asymptomatic moderate/severe aortic stenosis. NT-proBNP was determined in all patients, who were then followed up clinically. A clinical event was defined as surgery, hospital admission due to angina, heart failure or syncope, or death. A total of 51% were women, and the mean age was 74 years. Mean (SD) echocardiographic values were as follows: peak velocity 4.14 (0.87) m/s; mean gradient, 43.2 (16.0) mmHg; aortic valve area, 0.87 (0.72) cm2, and aortic valve area index, 0.49 (0.14) cm2/m2. The median NT-pro-BNP value was 490.0 [198.0-1312.0] pg/ml. There were 139 events during follow-up (median 12 months). The optimum NT-proBNP cut-point was 515 pg/ml, giving event-free survival rates at 6 months and 1 years of 93% and 57%, respectively, in patients with NT-proBNP <515 pg/ml compared with 50% and 31% in those with NT-proBNP >515 pg/ml. NT-proBNP determination provides prognostic information in patients with asymptomatic moderate/severe aortic stenosis.